Immunic Doubles Down On Lead Asset With New Data In Ulcerative Colitis

 
• By Jessica Merrill

The company is emphasizing development of vidofludimus calcium in multiple indications and deprioritizing izumerogant, an asset the company was developing in psoriasis and prostate cancer.

two roads
Immunic is exploring several paths forward for vidofludimus calcium • Source: Shutterstock

More from Clinical Trials

More from R&D